Allergy Drug Improves Function in Patients with Chronic Injury from Multiple Sclerosis
In Phase II Clinical Trial, Over-the-Counter Antihistamine Significantly Accelerated Nerve-Cell Signaling that had been Slowed by MS
The researchers said that the Phase II results, published online on Oct. 10, 2017, in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.
“To the best of our knowledge this is the first time a therapy has been able to reverse deficits caused by MS. It’s not a cure, but it’s a first step towards restoring brain function to the millions who are affected by this chronic, debilitating disease,” said the trial’s principal investigator, Ari Green, MD, also Debbie and Andy Rachleff Distinguished Professor of Neurology, chief of the Division of Neuroinflammation and Glial Biology, and medical director of the UCSF Multiple Sclerosis and Neuroinflammation Center.
Personal note: Under medical supervision, I will begin taking this medication on 10/23/2017. I will be taking the dermatological dose (2.68/BID), but still under the maximum recommended dose (2.68/TID).
There are other medical reasons for me to be on clemastine fumarate, but if it will provide any relief from MS then hallelujah and amen.
Complete story:
https://www.ucsf.edu/news/2017/10/40...iple-sclerosis
Lancet (original source):
http://www.thelancet.com/journals/la...t?elsca1=tlxpr
In Phase II Clinical Trial, Over-the-Counter Antihistamine Significantly Accelerated Nerve-Cell Signaling that had been Slowed by MS
The researchers said that the Phase II results, published online on Oct. 10, 2017, in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.
“To the best of our knowledge this is the first time a therapy has been able to reverse deficits caused by MS. It’s not a cure, but it’s a first step towards restoring brain function to the millions who are affected by this chronic, debilitating disease,” said the trial’s principal investigator, Ari Green, MD, also Debbie and Andy Rachleff Distinguished Professor of Neurology, chief of the Division of Neuroinflammation and Glial Biology, and medical director of the UCSF Multiple Sclerosis and Neuroinflammation Center.
Personal note: Under medical supervision, I will begin taking this medication on 10/23/2017. I will be taking the dermatological dose (2.68/BID), but still under the maximum recommended dose (2.68/TID).
There are other medical reasons for me to be on clemastine fumarate, but if it will provide any relief from MS then hallelujah and amen.
Complete story:
https://www.ucsf.edu/news/2017/10/40...iple-sclerosis
Lancet (original source):
http://www.thelancet.com/journals/la...t?elsca1=tlxpr
Comment